The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Bladder cancer does not always announce itself with dramatic pain or a sudden health crisis. In many people, the earliest bladder cancer symptoms look ordinary, brief, or easy to dismiss. A little ...

“This early clinical data validates a core premise: the physics of cancer can reveal what molecular tests routinely miss,” said Jean Pham, Founder & CEO of Cellens. “Our goal is to shift the standard ...

A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.

New research identifies distinct urinary metabolites linked to bladder cancer and recurrence, raising hope for non-invasive ...

Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...

Out of sight, out of mind. A new study suggests a common eye condition could be quietly masking one of the only early warning signs of bladder cancer — the 10th leading cause of cancer deaths in the ...